SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BTQ Technologies Corp

BTQQF is trending due to community discussions around its Nasdaq uplisting, the potential for increased exposure, and the shift to the new ticker symbol BTQ. Concerns about potential dilution and price manipulation are being weighed against bullish sentiment regarding the company's position in the quantum cybersecurity space and a possible upcoming 

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors assess its future growth potential amid discussions around government funding and domestic rare earth production. Community members are weighing the impact of strategic partnerships and production gains, while also debating potential connections to political figures. Some traders are closely watching technical indicators and options activity for potential entry points, while others express concerns about short-term volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to a recent downgrade from J.P. Morgan, which is fueling debate among investors about the company's valuation and future prospects in the AI and Bitcoin mining sectors. The community is actively discussing the validity of the downgrade, comparing it to other analysts' positive ratings, and speculating about potential loading by JPM. Some are focused on the company's transition to AI infrastructure and potential GPU commissioning.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to the FDA approval of Palsonify, a once-daily oral drug for acromegaly, with anticipation building for its market availability in early October. Community members are discussing the potential for significant sales and a possible short squeeze, as well as analyst price target upgrades. Despite recent gains, some traders believe the stock is undervalued given its pipeline and potential expansion into Europe.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses a mix of factors, including analyst upgrades citing AI and robotaxi potential, and debates over valuation. Some traders point to technical signals and anticipate further upward movement, while others express concerns about sales figures and potential pullbacks. Additionally, discussions around Elon Musk's involvement in the Epstein files are circulating.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as community members rally around the self-proclaimed "first ETF on Solana," with many highlighting the strong community and encouraging others to "load up" for a potential "meme season." Despite some skepticism, supporters express confidence in the project's long-term potential and encourage holding through market fluctuations. The project's branding and community-driven nature appear to be key talking points.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community focuses on its potential within the DEX and DeFi space, particularly its trending status and potential price movements. Bullish sentiment seems to be fueled by discussions around breaking resistance levels and predictions of continued upward momentum. Some traders are drawing comparisons to similar projects and anticipating substantial growth, while others urge caution and highlight the inherent volatility.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a mixed reaction to their recent $1.1 billion capital raise and a new AI hosting agreement with Fluidstack backed by Google; some investors are concerned about potential dilution, while others see it as a strategic move for long-term growth in the AI data center space. The community is actively debating whether the stock's dip represents a buying opportunity or a sign of underlying weakness, with discussions focusing on the offering's terms and the company's shift towards high-performance computing.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Silver prices are surging, hitting levels not seen in over a decade, fueled by a weaker dollar and anticipation of future Federal Reserve rate cuts; community members are actively discussing whether this momentum will continue and questioning the lag between spot silver prices and the SLV ETF. Some speculate that the rise is only the beginning of a larger bull run, while others are preparing for a potential pullback. Many messages also pointed to silver's use in AI and mining stocks as reasons for the price increases.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members speculate about potential partnerships with Apple and TSMC and how this might impact the company's growth and stock value. Traders are actively discussing potential price movements, with many eyeing the $40 mark, and attributing the stock's momentum to government support for domestic chip manufacturing. Some investors believe that Intel is undervalued compared to its peers, while others suggest caution, pointing to technical indicators and potential overbought conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Shares of Ocugen, Inc. (OCGN) rose 3% on Friday morning after the company reported a better-than-feared first-quarter (Q1) loss.The biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2025-financial">reported</a> a revenue of $1.5 million, up from $1 million in the corresponding quarter of 2024.Loss per share came in at $0.05, unchanged from the corresponding quarter of 2024, and better than the estimated loss of $0.06 per share.The company, which is developing gene therapies for blindness diseases, ended the quarter with cash and restricted cash totaling $38.1 million, compared to $58.8 million as of Dec. 31, 2024. It expects this will provide runway into the first quarter of 2026.CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the U.S. Food and Drug Administration (FDA) requesting approval for the distribution of three of its products in the next three years.“We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vision," he said.On Stocktwits, retail sentiment around Ocugen jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at high levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_9_57_35_AM_png_0d026d6926.webp" alt="Screenshot 2025-05-09 at 9.57.35 AM.png" width="630" height="63"><figcaption>OCGN's Sentiment Meter and Message Volume as of 9:24 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for the stock, citing the three upcoming FDA applications.<stembedurl>https://stocktwits.com/FannyChmelar/message/614075330</stembedurl>Another noted that the low cash reserve is expected in a company not selling products yet.<stembedurl>https://stocktwits.com/Slapshot22/message/614070848</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is down by 21% this year and 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-faces-moltiply-lawsuit/chiWtc6RblO">Google Faces $3.3B Lawsuit From Italy’s Moltiply Group: Search Giant Disagrees With ‘Exorbitant’ Private Damages Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Equity

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.


Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a quarterly earnings report that exceeded revenue expectations.The biopharmaceutical company, which focuses on developing gene therapies for eye diseases, reported a fourth-quarter loss of $0.05 per share, in line with estimates.&nbsp;Revenue was $764,000, down from $1.4 million a year ago due to reduced co-development services, but still well above the $400,000 analysts expected.Ocugen's modifier gene therapy platform includes OCU400, OCU410, and OCU410ST, which target inherited retinal diseases (IRDs) and conditions like dry age-related macular degeneration (dAMD) and Stargardt disease.Its OCU400 is in Phase 3 clinical trials for retinitis pigmentosa (RP) in the U.S. and Canada, with enrollment expected to be completed in the first half of 2025.OCU500, Ocugen's inhaled mucosal COVID-19 vaccine, recently received FDA clearance for an Investigational New Drug (IND) application.&nbsp;The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor a Phase 1 trial evaluating two delivery routes — lung inhalation and nasal spray.To extend its cash runway into the first quarter of 2026 and support ongoing clinical trials, Ocugen secured $65 million in equity and debt financing in the second half of 2024.&nbsp;In May, the company was included in the Russell Index.On Stocktwits, sentiment for Ocugen ended Wednesday higher within the 'bullish' zone, with message volume surging 32%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCGN_sentiment_and_message_volume_as_of_March_5_42ff8160da.png" alt="OCGN sentiment and message volume as of March 5.png" width="1316" height="302"><figcaption>OCGN sentiment and message volume as of March 5 | source: Stocktwits</figcaption></figure>One retail trader said the value of Ocugen's pipeline "is insane and I'll be holding when it comes to fruition."<stembedurl>https://stocktwits.com/SGimvesting/message/606846472</stembedurl>Another was hopeful after pointing out that CEO Shankar Musunuri confirmed NIAID's funding support for OCU500's Phase 1 trial next quarter.<stembedurl>https://stocktwits.com/Hamiltoes/message/606856276</stembedurl>Ocugen's ambitious roadmap targets three potential Biologics License Applications (BLAs) between 2026 and 2028, covering RP, Stargardt, and geographic atrophy (GA).However, Ocugen faces a significant short interest rate of 20.7%, according to Koyfin data.&nbsp;The stock trades 1,033% below the average analyst price target of $6.50, with two analysts rating it a 'buy' and two a 'strong buy.'Shares of Ocugen are down over 33% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the companys shareholders. Since July 2024, shares of Ocugens stock have declined in value from a trading...

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible...

Peering Into Ocugen's Recent Short Interest

OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm OCGN

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the Class Period...

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) for violations of 10(b) and...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCGN News

OCGN Ocugen Inc